Ovarian cancer and hormone replacement therapy.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Lancet

• Publication date

  2007-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(07)61436-6PMID 17869627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider

  2007cited by this paper
• Ovarian cancer and hormone replacement therapy in the Million Women Study

  2007cited by this paper
• Ovarian cancer and hormone replacement therapy in the Million Women Study.

  2007cited by this paper

• Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments

  2025cites this paper
• HyperFoods: Machine intelligent mapping of cancer-beating molecules in foods

  2019cites this paper
• Vascular endothelium dysfunction: a conservative target in metabolic disorders

  2018cites this paper
• Hormone therapy and ovarian cancer.

  2015cites this paper
• [HRT and ovarian cancer risk].

  2015cites this paper
• IL6 induces TAM resistance via kinase-specific phosphorylation of ERα in OVCA cells.

  2015cites this paper
• A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy

  2015cites this paper
• The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control

  2015cites this paper
• Le traitement hormonal de la ménopause (THM) chez les jeunes médecins généralistes de Gironde : connaissances, attitudes et pratiques

  2015cites this paper
• Effect of Hormone Replacement Therapy on Osteoporosis and Its Complication on Adults Female Albino Rats

  2014cites this paper
• A Case Control study of Lifestyle Factors in the Aetiology of Ovarian Cancer

  2013cites this paper
• Differential induction of LRP16 by liganded and unliganded estrogen receptor alpha in SKOV3 ovarian carcinoma cells.

  2009cites this paper
• Association of Ovarian and Uterine Cancers With Postmenopausal Hormonal Treatments

  2008cites this paper
• Hormone replacement as the first-line prevention for postmenopausal osteoporosis

  2007cites this paper